These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23033257)

  • 1. Post-market drug safety evidence sources: an analysis of FDA drug safety communications.
    Ishiguro C; Hall M; Neyarapally GA; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 5. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 6. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striking the right balance.
    Nat Rev Drug Discov; 2006 Nov; 5(11):879. PubMed ID: 17117516
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
    Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should new drugs be avoided?
    Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722
    [No Abstract]   [Full Text] [Related]  

  • 11. Contributing to drug safety.
    Johnson JM
    Am J Hosp Pharm; 1990 Jun; 47(6):1280. PubMed ID: 2368721
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
    Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
    Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 14. The drug safety review process.
    Somberg J
    Am J Ther; 2007; 14(2):119. PubMed ID: 17414577
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 16. Report hits FDA to revamp safety oversight.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Jul; 98(13):884-5. PubMed ID: 16818849
    [No Abstract]   [Full Text] [Related]  

  • 17. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication risk must be balanced with benefit, not fear.
    Jones KW
    Ann Pharmacother; 2010 Apr; 44(4):737-9. PubMed ID: 20332340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.